Andrew Balo - DexCom President
| DXCM Stock | USD 72.83 1.63 2.19% |
President
Mr. Andrew K. Balo serves as Executive Vice President Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development of DexCom Inc. He has served as our Executive Vice President of Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development since May 2016. From January 2015 until April 2016 Mr. Balo served as our Executive Vice President, Clinical, Regulatory and Quality. From March 2008 to January 2015, Mr. Balo served as our Senior Vice President of Clinical and Regulatory Affairs, and from February 2002 to March 2008, served as our Vice President of Clinical and Regulatory Affairs. From June 1999 to February 2002, Mr. Balo served as Vice President, Regulatory and Clinical Affairs of Innercool Therapies, Inc., a medical technology company. Mr. Balo has held several positions at St. Jude Medical including Clinical, Vice President, Quality, Regulatory and Clinical Affairs and was an officer of the company since 2016.
| Age | 76 |
| Tenure | 8 years |
| Address | 6340 Sequence Drive, San Diego, CA, United States, 92121 |
| Phone | 858 200 0200 |
| Web | https://www.dexcom.com |
DexCom Management Efficiency
The company has return on total asset (ROA) of 0.0606 % which means that it generated a profit of $0.0606 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.3206 %, meaning that it created $0.3206 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to grow to 0.09. Also, Return On Capital Employed is likely to grow to 0.13. At this time, DexCom's Net Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Intangible Assets is likely to grow to about 141.2 M, while Debt To Assets are likely to drop 0.37.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ivan Tornos | Zimmer Biomet Holdings | 49 | |
| Donald Bobo | Edwards Lifesciences Corp | 62 | |
| JeanLuc Lemercier | Edwards Lifesciences Corp | 67 | |
| Richard Kuntz | Medtronic PLC | 63 | |
| Karen Parkhill | Medtronic PLC | 59 | |
| Robert Hoedt | Medtronic PLC | 64 | |
| Geoffrey Martha | Medtronic PLC | 54 | |
| Andrew Lane | Abbott Laboratories | 49 | |
| Frank Chan | Medtronic PLC | N/A | |
| Hooman Hakami | Medtronic PLC | 48 | |
| Maulik Nanavaty | Boston Scientific Corp | ||
| Desiree RallsMorrison | Boston Scientific Corp | 54 | |
| John Capek | Abbott Laboratories | 59 | |
| Derek Davis | Zimmer Biomet Holdings | 51 | |
| Eric Benjamin | Insulet | 41 | |
| Carrie Anderson | Integra LifeSciences Holdings | 55 | |
| Jeffrey Mosebrook | Integra LifeSciences Holdings | 48 | |
| Michael Coyle | Medtronic PLC | 57 | |
| Carol Surface | Medtronic PLC | 54 | |
| Scott Olson | Boston Scientific Corp | 51 | |
| Steven Jandrich | Inspire Medical Systems | 57 | |
Management Performance
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0606 |
DexCom Inc Leadership Team
Elected by the shareholders, the DexCom's board of directors comprises two types of representatives: DexCom inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DexCom. The board's role is to monitor DexCom's management team and ensure that shareholders' interests are well served. DexCom's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DexCom's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shelly Selvaraj, Senior Officer | ||
| Leverne Marsh, Executive Marketing | ||
| Matthew Dolan, Corporate Strategy | ||
| Teri Lawver, Executive Officer | ||
| Jacob Leach, Executive COO | ||
| Donald Abbey, Quality Services | ||
| Jereme Sylvain, CFO VP | ||
| Jereme CPA, CFO VP | ||
| Paul Flynn, Ex Revenue | ||
| Kevin Sayer, CEO and President and Director | ||
| Girish Naganathan, Executive CTO | ||
| Michael Brown, Executive Officer | ||
| Stacey Stewart, Senior Officer | ||
| Sadie Stern, Executive Officer | ||
| Steven Pacelli, Executive VP of Strategy and Corporate Devel. | ||
| Sean Christensen, Director Relations | ||
| Andrew Balo, Senior Vice President - Clinical and Regulatory Affairs |
DexCom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DexCom a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.32 | ||||
| Return On Asset | 0.0606 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 28.55 B | ||||
| Shares Outstanding | 390.6 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 96.86 % | ||||
| Number Of Shares Shorted | 9.36 M | ||||
| Price To Earning | 245.31 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DexCom. If investors know DexCom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DexCom listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.157 | Earnings Share 1.65 | Revenue Per Share 10.089 | Quarterly Revenue Growth 0.02 | Return On Assets 0.0606 |
The market value of DexCom Inc is measured differently than its book value, which is the value of DexCom that is recorded on the company's balance sheet. Investors also form their own opinion of DexCom's value that differs from its market value or its book value, called intrinsic value, which is DexCom's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DexCom's market value can be influenced by many factors that don't directly affect DexCom's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DexCom's value and its price as these two are different measures arrived at by different means. Investors typically determine if DexCom is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DexCom's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.